Morgan Stanley restated their equal weight rating on shares of Sage Therapeutics ( NASDAQ:SAGE – Free Report ) in a research report report published on Thursday morning, Benzinga reports. The firm currently has a $49.00 target price on the biopharmaceutical company's stock. A number of other equities analysts also recently issued reports on SAGE. Bank of America increased their price target on Sage Therapeutics from $61.00 to $66.00 in a research report on Thursday, June 15th. Scotiabank started coverage on Sage Therapeutics in a research report on Thursday, July 27th.

https://www.dailypolitical.com/2023/08/06/sage-therapeutics-sage-equal-weight-rating-reiterated-at-morgan-stanley.html

#dailypolitical